AFP
BBH icon

Ausdal Financial Partners’s VanEck Biotech ETF BBH Stock Holding History

Ausdal Financial Partners’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,003
Closed -$127K – 290
2015
Q4 		$127K Buy
+1,003
New +$123K 0.06% 265

Other funds holding BBH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $14.2B AUM 20.68% 1-Year Est. Return

Ausdal Financial Partners's BBH Position: Q1 2016 in Review

Ausdal Financial Partners sold out of VanEck Biotech ETF (BBH) in Q1 2016, closing a stake of 1,003 shares — an estimated $127K sold.

Ausdal Financial Partners first reported a position in BBH in Q4 2015 and held it in 1 quarter. The position peaked at $127K in Q4 2015. 71 funds tracked by Wall St. Rank hold BBH as of Q1 2016.

  • Ausdal Financial Partners reported no remaining VanEck Biotech ETF position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 1,003 VanEck Biotech ETF shares in Q1 2016, an estimated $127K.
  • Ausdal Financial Partners first reported a position in VanEck Biotech ETF in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's VanEck Biotech ETF position peaked at $127K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.